Baxdrostat

Promising new devices and emerging drug classes may improve BP control for some patients with difficult-to-treat hypertension, but clinicians must first address the structural inequities that impact access to care, according to a speaker.

NEW ORLEANS — Baxdrostat, an aldosterone synthase inhibitor, did not lower systolic BP compared with placebo at 8 weeks in patients with uncontrolled hypertension, but nonadherence may have been a factor, researchers reported.